PTSDSubstance Use Disorders (SUD)Interpersonal Functioning & Social ConnectednessMDMA

Associations between MDMA/ecstasy use and physical health in a U.S. population-based survey sample

Using US National Survey on Drug Use and Health data (2005–2018), the study found that lifetime MDMA (ecstasy) use was associated with lower risk of overweight/obesity and reduced odds of past-year heart condition/cancer, hypertension and diabetes, and with higher odds of reporting better overall health. These associations remained after adjustment for multiple confounders, though the authors note longitudinal studies and clinical trials are needed to test causality.

Authors

  • Otto Simonsson
  • Peter Hendricks

Published

Journal of Psychopharmacology
individual Study

Abstract

Introduction

3,4-Methylenedioxymethamphetamine (MDMA/“ecstasy”) is an empathogen that can give rise to increased pleasure and empathy and may effectively treat post-traumatic stress disorder. Although prior research has demonstrated associations between ecstasy use and favorable mental health outcomes, the associations between ecstasy and physical health have largely been unexplored. Thus, the goal of this study was to examine the associations between ecstasy use and physical health in a population-based survey sample.

Method

This study utilized data from the National Survey on Drug Use and Health (2005–2018), a yearly survey that collects information on substance use and health outcomes in a nationally representative sample of U.S. adults. We used multinomial, ordered, and logistic regression models to test the associations between lifetime ecstasy use and various markers of physical health (self-reported body mass index, overall health, past year heart condition and/or cancer, past year heart disease, past year hypertension, and past year diabetes), controlling for a range of potential confounders.

Results

Lifetime ecstasy use was associated with significantly lower risk of self-reported overweightness and obesity (adjusted relative risk ratio range: 0.55–0.88) and lower odds of self-reported past year heart condition and/or cancer (adjusted odds ratio (aOR): 0.67), hypertension (aOR: 0.85), and diabetes (aOR: 0.58). Ecstasy use was also associated with significantly higher odds of better self-reported overall health (aOR: 1.18).

Conclusion

Ecstasy shares protective associations with various physical health markers. Future longitudinal studies and clinical trials are needed to more rigorously test these associations.

Available with Blossom Pro

Research Summary of 'Associations between MDMA/ecstasy use and physical health in a U.S. population-based survey sample'

Introduction

Jones and colleagues situate the study within renewed clinical and research interest in MDMA (ecstasy), noting its empathogenic effects, acute physiological effects (for example increased heart rate and blood pressure), and recent promise as an adjunct to psychotherapy for treatment-resistant post-traumatic stress disorder. Earlier population-based work has reported protective associations between classic psychedelic use and several markers of physical health, and some observational and clinical reports suggest MDMA-assisted therapy can reduce comorbid conditions that influence physical health. Despite these threads, the authors identify a gap: few studies have examined associations between ecstasy use and broad markers of physical health in population-representative samples. This study therefore aimed to test whether lifetime ecstasy use is associated with a range of self-reported physical health markers in a nationally representative U.S. survey. Specifically, the investigators sought to replicate and extend prior findings on classic psychedelics by examining relationships between lifetime ecstasy use and body mass index (BMI), overall self-rated health, and several past-year cardiometabolic and disease outcomes.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

Study Details

References (27)

Papers cited by this study that are also in Blossom

MDMA-assisted therapy significantly reduces eating disorder symptoms in a randomized placebo-controlled trial of adults with severe PTSD

Brewerton, T. D., Wang, J. B., Lafrance, A. et al. · Journal of Psychiatric Research (2022)

50 cited
Breakthrough for trauma treatment: safety and efficacy of MDMA-assisted psychotherapy compared to paroxetine and sertraline

Feduccia, A. A., Jerome, L., Yazar-Klosinski, B. et al. · Frontiers in Psychiatry (2019)

Cessation and reduction in alcohol consumption and misuse after psychedelic use

Garcia-Romeu, A., Davis, A. K., Fire Erowid et al. · Journal of Psychopharmacology (2019)

211 cited
Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance

Griffiths, R. R., Richards, W. A., Mccann, U. et al. · Journal of Psychopharmacology (2006)

The relationships of classic psychedelic use with criminal behavior in the United States adult population

Hendricks, P. S., Crawford, M. S., Cropsey, K. L. et al. · Journal of Psychopharmacology (2017)

Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population

Hendricks, P. S., Thorne, C. B., Clark, B. et al. · Journal of Psychopharmacology (2015)

345 cited
Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function

Johnson, M. W., Hendricks, P. S., Barrett, F. S. et al. · Pharmacology and Therapeutics (2019)

23 cited
Show all 27 references
22 cited
45 cited
Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA

Grob, C. S., Mithoefer, M. C., Brewerton, T. D. · Lancet Psychiatry (2016)

Association Between Lifetime Classic Psychedelic Use and Hypertension in the Past Year

Simonsson, O., Hendricks, P. S., Carhart-Harris, R. et al. · Hypertension (2021)

28 cited
Associations between lifetime classic psychedelic use and cardiometabolic diseases

Simonsson, O., Osika, W., Carhart-Harris, R. L. et al. · Scientific Reports (2021)

Associations between lifetime classic psychedelic use and markers of physical health

Simonsson, O., Sexton, J. D., Hendricks, P. S. · Journal of Psychopharmacology (2021)

65 cited
Psychedelics and health behaviour change

Teixeira, P. J., Johnson, M. W., Timmermann, C. et al. · Journal of Psychopharmacology (2021)

Psychological and cardiovascular effects and short-term sequelae of MDMA (“ecstasy”) in MDMA-naıve healthy volunteers

Vollenweider, F. X., Gamma, A., Liechti, M. et al. · Neuropsychopharmacology (1998)

450 cited

Cited By (1)

Papers in Blossom that reference this study

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.